How the evidence outlook works ↗
Featured trials The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Non-Small Cell Lung Cancer · investigational in the US · Featured evidence · 3 Biliary Tract Cancer · investigational in the US · Featured evidence · 3 Hepatocellular Carcinoma · investigational in the US · Review pending Gastric Cancer · investigational in the US · Review pending Urothelial Carcinoma · investigational in the US · Review pending Endometrial Cancer · investigational in the US · Review pending investigational in the US Featured evidence · 3
Trial Phase Endpoint Key result Signal Source NCT06627647
NCT06627647 · Non-squamous Non-small Cell Lung Cancer
3 Overall survival (OS) (Up to approximately 6 years); Progression-free survival (PFS) (Up to approximately 6 years)2030-11-18
In progress: results expected 18 Nov 2030 not yet graded link ↗
View 2 more trials ARTEMIDELung04
NCT06868277 · Carcinoma, Non-Small Cell Lung
3 Overall Survival (OS) (Up to approximately 5 years); Progression-Free Survival (PFS) (Up to approximately 5 years)2030-01-17
In progress: results expected 17 Jan 2030 not yet graded link ↗ TROPION-Lung10
NCT06357533 · Non-Small Cell Lung Cancer
3 Progression-Free Survival (PFS) in TROP2 biomarker positive participants. (Approximately 4 years); Overall Survival (OS) in TROP2 biomarker positive participants. (Approximately 6 years)2029-12-28
In progress: results expected 28 Dec 2029 not yet graded link ↗
All registered studies Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
All indications (38) Biliary Tract Cancer (5) Endometrial Cancer (3) Gastric Cancer (9) Hepatocellular Carcinoma (2) Non-Small Cell Lung Cancer (14) Urothelial Carcinoma (2) Other / comorbidity (9)
Phase 3 (13) Biliary Tract Cancer
NCT06109779 · AstraZeneca
2023-12-04 – 2030-05-03 · Biliary Tract Cancer
What this study did
NCT07221253 · AstraZeneca
2025-12-04 – 2029-07-31 · Biliary Tract Cancer
What this study did
NCT06467357 · AstraZeneca
2024-08-12 – 2029-05-16 · Biliary Tract Cancer
What this study did
Endometrial Cancer
NCT06989112 · AstraZeneca
2025-03-27 – 2031-02-19 · Endometrial Cancer
What this study did
Gastric Cancer
NCT07431281 · AstraZeneca
2026-02-03 – 2031-10-27 · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
What this study did
NCT06764875 · AstraZeneca
2025-03-01 – 2030-12-09 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
Hepatocellular Carcinoma
NCT06921785 · AstraZeneca
2025-05-06 – 2030-03-15 · Hepatocellular Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT06868277 · AstraZeneca
2025-04-10 – 2030-12-02 · Carcinoma, Non-Small Cell Lung
What this study did
NCT06627647 · AstraZeneca
2024-11-27 – 2030-11-18 · Non-squamous Non-small Cell Lung Cancer
What this study did
NCT06692738 · AstraZeneca
2024-11-18 – 2030-07-01 · Non-small Cell Lung Cancer
What this study did
NCT06357533 · AstraZeneca
2024-04-11 – 2029-12-28 · Non-Small Cell Lung Cancer
What this study did
NCT06564844 · AstraZeneca
2024-10-15 – 2027-03-31 · Non-small Cell Lung Cancer
What this study did
Urothelial Carcinoma
NCT07720284 · AstraZeneca
2026-07-16 – 2032-11-23 · High-risk Muscle Invasive Urothelial Carcinoma
What this study did
Phase 2 (14) Biliary Tract Cancer
NCT05489211 · AstraZeneca
2022-09-06 – 2027-10-01 · Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer, Colorectal Cancer, Urothelial Cancer, Biliary Tract Cancer
What this study did
Gastric Cancer
NCT07788664 · Vall d'Hebron Institute of Oncology
2026-12-01 – 2030-06-01 · Advanced Gastric Cancer
What this study did
NCT06630130 · Jeeyun Lee
2025-01-22 – 2029-06-30 · Stomach Neoplasms
What this study did
NCT05702229 · AstraZeneca
2023-01-16 – 2029-05-31 · Gastric Cancer
What this study did
NCT04379596 · AstraZeneca
2020-06-03 – 2027-05-04 · Gastric Cancer
What this study did
Hepatocellular Carcinoma
NCT05775159 · AstraZeneca
2023-04-24 – 2027-10-28 · Hepatocellular Carcinoma, Biliary Tract Cancer
What this study did
Non-Small Cell Lung Cancer
NCT05061550 · AstraZeneca
2022-04-14 – 2030-05-28 · Non-small Cell Lung Cancer
What this study did
NCT07098338 · AstraZeneca
2025-08-07 – 2029-04-06 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT07069712 · AstraZeneca
2025-07-17 – 2029-07-16 · Gastroesophageal Adenocarcinoma
What this study did
NCT07128290 · Federation Francophone de Cancerologie Digestive
2025-10-30 – 2029-04-30 · Intrahepatic Cholangiocarcinoma (Icc)
What this study did
NCT06569225 · University Health Network, Toronto
2024-12-15 – 2028-12-31 · Cholangiocarcinoma Resectable
What this study did
NCT05414032 · University Health Network, Toronto
2023-07-12 – 2028-07 · Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
What this study did
NCT03741426 · CCTU- Cancer Theme
2020-07-27 – 2027-12-30 · Renal Cell Cancer
What this study did
Phase 1/2 (5) Gastric Cancer
NCT06005493 · AstraZeneca
2023-07-11 – 2029-03-16 · Gastric Cancer, Gastro-esophageal Junction Cancer, Pancreatic Ductal Adenocarcinoma, Esophageal Adenocarcinoma
What this study did
Non-Small Cell Lung Cancer
NCT07115043 · AstraZeneca
2025-07-29 – 2029-10-02 · Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Gastric Cancer/Gastroesophageal Junction Cancer, High Grade Serous Ovarian Carcinoma
What this study did
NCT06996782 · AstraZeneca
2025-11-24 – 2029-02-23 · Advanced or Metastatic Non-small Cell Lung Cancer
What this study did
NCT04995523 · AstraZeneca
2021-09-14 – 2028-06-01 · Non-Small-Cell Lung Carcinoma
What this study did
NCT05123482 · AstraZeneca
2021-10-18 – 2027-09-29 · Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer, Squamous Non-Small Cell Lung Cancer
What this study did
Phase 1 (6) Non-Small Cell Lung Cancer
NCT04686305 · AstraZeneca
2021-03-09 – 2027-06-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT04612751 · AstraZeneca
2021-02-02 – 2027-05-04 · Advanced or Metastatic NSCLC
What this study did
NCT03819465 · AstraZeneca
2018-12-27 – 2026-07-01 · Metastatic Non-Small Cell Lung Cancer (NSCLC)
What this study did
Other / comorbidity
NCT04541108 · Presage Biosciences
2021-07-26 – 2031-12 · Solid Tumor
What this study did
NCT07161414 · AstraZeneca
2025-11-25 – 2029-07-24 · Advanced Solid Tumors
What this study did
NCT06366451 · Presage Biosciences
2024-05-22 – 2026-03-25 · Head and Neck Squamous Cell Carcinoma
What this study did
Competitive landscape 1 other tracked programme targets this mechanism, none of them ahead of this one.
Biliary Tract Cancer Endometrial Cancer Gastric Cancer Hepatocellular Carcinoma Non-Small Cell Lung Cancer Urothelial Carcinoma List view
This drug's own stage for Biliary Tract Cancer: Phase 3 . Competitors below are sorted furthest-along first.
Upcoming events (33 total) Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Email me about these readouts Follow Rilvegostomig to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link . The calendar updates when a registry date moves.
2027 (10) May 2027 (1) Phase 2 Gastric Cancer Active not recruiting
Est. primary completion 2027-05-04 ·
NCT04379596 ·
CT.gov ↗ What to watch
June 2027 (1) Phase 1 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2027-06-30 ·
NCT04686305 ·
CT.gov ↗ What to watch
July 2027 (1) Phase 1 Advanced Solid Tumors Recruiting
Est. primary completion 2027-07-19 ·
NCT07161414 ·
CT.gov ↗ What to watch
September 2027 (2) Phase 2 Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Recruiting
Est. primary completion 2027-09 ·
NCT05414032 ·
CT.gov ↗ What to watch
Phase 1/2 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2027-09-29 ·
NCT05123482 ·
CT.gov ↗ What to watch
October 2027 (1) Phase 2 Biliary Tract Cancer Recruiting
Est. primary completion 2027-10-01 ·
NCT05489211 ·
CT.gov ↗ What to watch
November 2027 (2) Phase 2 Gastroesophageal Adenocarcinoma Recruiting
Est. primary completion 2027-11-09 ·
NCT07069712 ·
CT.gov ↗ What to watch
Phase 2 Gastric Cancer Recruiting
Est. primary completion 2027-11-30 ·
NCT05702229 ·
CT.gov ↗ What to watch
December 2027 (2) Phase 2 Renal Cell Cancer Recruiting
Est. primary completion 2027-12-30 ·
NCT03741426 ·
CT.gov ↗ What to watch
Phase 2 Cholangiocarcinoma Resectable Not yet recruiting
Est. primary completion 2027-12-31 ·
NCT06569225 ·
CT.gov ↗ What to watch
2028 (3) June 2028 (2) Phase 1/2 Non-Small Cell Lung Cancer Active not recruiting
Est. primary completion 2028-06-01 ·
NCT04995523 ·
CT.gov ↗ What to watch
Phase 3 Biliary Tract Cancer Recruiting
Est. primary completion 2028-06-12 ·
NCT06467357 ·
CT.gov ↗ What to watch
October 2028 (1) Phase 2 Gastric Cancer Recruiting
Est. primary completion 2028-10-30 ·
NCT06630130 ·
CT.gov ↗ What to watch
2029 (11) January 2029 (2) Phase 3 Biliary Tract Cancer Active not recruiting
Est. primary completion 2029-01-02 ·
NCT06109779 ·
CT.gov ↗ What to watch
Phase 3 Endometrial Cancer Recruiting
Est. primary completion 2029-01-19 ·
NCT06989112 ·
CT.gov ↗ What to watch
February 2029 (1) Phase 1/2 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2029-02-23 ·
NCT06996782 ·
CT.gov ↗ What to watch
March 2029 (1) Phase 1/2 Gastric Cancer Recruiting
Est. primary completion 2029-03-16 ·
NCT06005493 ·
CT.gov ↗ What to watch
April 2029 (3) Phase 2 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2029-04-06 ·
NCT07098338 ·
CT.gov ↗ What to watch
Phase 3 Gastric Cancer Recruiting
Est. primary completion 2029-04-27 ·
NCT06764875 ·
CT.gov ↗ What to watch
Phase 2 Intrahepatic Cholangiocarcinoma (Icc) Not yet recruiting
Est. primary completion 2029-04-30 ·
NCT07128290 ·
CT.gov ↗ What to watch
July 2029 (1) Phase 3 Biliary Tract Cancer Recruiting
Est. primary completion 2029-07-31 ·
NCT07221253 ·
CT.gov ↗ What to watch
August 2029 (1) Phase 3 Gastric Cancer Recruiting
Est. primary completion 2029-08-16 ·
NCT07431281 ·
CT.gov ↗ What to watch
October 2029 (1) Phase 1/2 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2029-10-02 ·
NCT07115043 ·
CT.gov ↗ What to watch
December 2029 (1) Phase 3 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2029-12-28 ·
NCT06357533 ·
CT.gov ↗ What to watch
2030 (8) January 2030 (1) Phase 3 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2030-01-17 ·
NCT06868277 ·
CT.gov ↗ What to watch
March 2030 (1) Phase 3 Hepatocellular Carcinoma Recruiting
Est. primary completion 2030-03-15 ·
NCT06921785 ·
CT.gov ↗ What to watch
May 2030 (1) Phase 2 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2030-05-28 ·
NCT05061550 ·
CT.gov ↗ What to watch
June 2030 (1) Phase 2 Gastric Cancer Not yet recruiting
Est. primary completion 2030-06-01 ·
NCT07788664 ·
CT.gov ↗ What to watch
July 2030 (1) Phase 3 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2030-07-01 ·
NCT06692738 ·
CT.gov ↗ What to watch
September 2030 (1) Phase 3 Urothelial Carcinoma Recruiting
Est. primary completion 2030-09-11 ·
NCT07720284 ·
CT.gov ↗ What to watch
November 2030 (1) Phase 3 Non-Small Cell Lung Cancer Recruiting
Est. primary completion 2030-11-18 ·
NCT06627647 ·
CT.gov ↗ What to watch
December 2030 (1) Phase 2 Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer … Recruiting
Est. primary completion 2030-12 ·
NCT01042379 ·
CT.gov ↗ What to watch
2031 (1) December 2031 (1) Phase 1 Solid Tumor Active not recruiting
Est. primary completion 2031-12 ·
NCT04541108 ·
CT.gov ↗ What to watch
See the full readout calendar ↗